The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tumor gene signature associated with neurotoxicity in R/R B-ALL patients treated with JCAR015, a CD19-directed CAR T cell product.
 
N. Eric Olson
Employment - Juno Therapeutics
Research Funding - Juno Therapeutics
Patents, Royalties, Other Intellectual Property - Juno Therapeutics
 
Seamus P. Ragan
Employment - Juno Therapeutics
Stock and Other Ownership Interests - Juno Therapeutics
Patents, Royalties, Other Intellectual Property - Juno Therapeutics
 
Stefan Ponko
Employment - Juno Therapeutics
Stock and Other Ownership Interests - Aptevo Therapeutics; Idera; Juno Therapeutics
 
Nikolaus S. Trede
Employment - Juno Therapeutics
Stock and Other Ownership Interests - Juno Therapeutics
 
Howard Marvin Stern
Employment - Infinity Pharmaceuticals; Juno Therapeutics; Psychology private practice (I)
Stock and Other Ownership Interests - Infinity Pharmaceuticals; Juno Therapeutics
Patents, Royalties, Other Intellectual Property - Gene expression markers of tumor resistance to HER2 inhibitor treatment; PI3 kinase isoform combination therapies; Treatment of cancers using PI3 kinase isoform modulators
Travel, Accommodations, Expenses - Infinity Pharmaceuticals; Juno Therapeutics
 
Claire L. Sutherland
Employment - Juno Therapeutics
Stock and Other Ownership Interests - Juno Therapeutics
Research Funding - Juno Therapeutics
Patents, Royalties, Other Intellectual Property - Juno Therapeutics
Other Relationship - Juno Therapeutics